Intravacc launches hybrid business model to drive innovation and growth Bilthoven, the Netherlands, 16 September 2021 – Intravacc, a global leader in translational research and the development of vaccines against infectious diseases and therapeutic vaccines, today launches its new hybrid…

• Hybrid model: CDMO services and development of a proprietary vaccine pipeline
• Intravacc will also put emphasis on the therapeutic vaccine market
• Intravacc’s proprietary vaccine portfolio will mainly focus on intranasal administration
• Intravacc launches promotional campaign, supporting the funding of a phase I clinical trial with the Avacc 10 nasal spray vaccine

Intravacc’s inactivated polio vaccine, out licensed to Sinovac, receives market authorization in China Bilthoven, the Netherlands, 20 July 2021 – Intravacc, a world leader in translational research and development of vaccines for infectious diseases and therapeutics, today announced that the…

• Sabin-IPV polio vaccine developed by Intravacc contributes to the eradication of polio
• Sinovac’s polio vaccine (sIPV) receives market authorization from the NMPA in China
• Intravacc’s cell technology also used for the development of Sinovac’s Covid-19 vaccine that was introduced on the market recently and is currently under rolling review by EMA

Intravacc announces positive pre-clinical data for its OMV-based Lyme vaccine Bilthoven, the Netherlands, 13 April 2021 – Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme…

• Neisserial OMV based Lyme vaccine elicit high antibody titers in mice
• Two conventional vaccines based on Intravacc's OMV platform and VEO cell platform